



## Krystal Biotech to Present at TD Cowen 46th Annual Health Care Conference

February 24, 2026

PITTSBURGH, Feb. 24, 2026 (GLOBE NEWSWIRE) -- [Krystal Biotech, Inc.](#) (the "Company") (NASDAQ: KRY5) today announced that the Company will participate in the TD Cowen 46th Annual Health Care Conference on March 3, 2026, in Boston. Company executives will take part in a fireside chat scheduled at 3:10 pm ET and host investor meetings throughout the day.

A webcast of the presentation will be available [here](#) beginning at 3:10 pm ET on Tuesday, March 3, 2026 and will be posted on the Investors section of the Company's [website](#).

### **About Krystal Biotech, Inc.**

Krystal Biotech, Inc. (NASDAQ: KRY5) is a fully integrated, commercial-stage, global biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseases with high unmet medical needs. VYJUVEK<sup>®</sup>, the Company's first commercial product, is the first-ever redosable gene therapy and the first genetic medicine approved in the United States, Europe, and Japan for the treatment of dystrophic epidermolysis bullosa. The Company is rapidly advancing a robust preclinical and clinical pipeline of investigational genetic medicines. Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. For more information, please visit <http://www.krystalbio.com>, and follow @KrystalBiotech on [LinkedIn](#) and [X](#) (formerly Twitter).


### **CONTACT**

#### **Investors and Media:**

Stéphane Paquette, PhD

Krystal Biotech

[spaquette@krystalbio.com](mailto:spaquette@krystalbio.com)



Source: Krystal Biotech, Inc.